Results of a six-month intervention trial on 95 adult tea drinkers.
Black tea is a major contributor of dietary flavonoids to the global population and, like other dietary sources of flavonoids, it appears drinking the tea may have a positive effect on blood pressure.
Australian researchers recruited 95 adult tea drinkers for a six-month intervention trial. Participants were instructed to follow a low-flavonoid diet with the exception of black tea, which was assigned at three cups daily during a four-week run-in period. After the four weeks, participants were assigned to consume three cups of black tea solids (containing 429 mg of polyphenols and 96 mg of caffeine) or flavor- and caffeine-matched placebo daily for six months.
Those who consumed black tea solids experienced mean reductions in systolic blood pressure by 2.7 mm Hg and 2.0 mm Hg at three and six months respectively, compared to baseline. Diastolic blood pressure also decreased, with drops of 2.3 mm Hg and 2.1 mm Hg at three and six months. Between-group differences in gender, starting blood pressure, age, and other key variables were considered by the researchers to be insignificant.
Previous intervention trials with black tea have failed to observe a blood pressure benefit, wrote the researchers behind this new study. But they believe those studies may have been too low-powered and time-constrained to detect a benefit. The results of the new trial, published in the journal Archives of Internal Medicine, reflect what could be a serious benefit to tea drinkers at large.
“At a population level, the observed differences in [blood pressure] would be associated with a 10% reduction in the prevalence of hypertension and a 7% to 10% reduction in the risk of cardiovascular disease,” the authors said.
Funding for the study was provided by the National Health and Medical Research Council of Australia and Unilever (Vlaardingen, the Netherlands), which owns the Lipton tea brand.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.